Funding for this research was provided by:
National Institute of General Medical Sciences (R01 GM130777, R35GM143056)
Brigham Research Institute (President's Scholar Award)
American College of Gastroenterology (Junior Faculty Development Award)
BWH Precision Medicine Institute
Hatch Family Foundation
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK056338)
National Institute of Allergy and Infectious Diseases (R21AI154075)
Received: 29 November 2021
Accepted: 2 May 2022
First Online: 9 June 2022
: All study participants signed informed consent prior to study procedures. The protocol was approved by the Brigham and Women’s Hospital Institutional Review Board (#2014P000272).
: Not applicable.
: No industry support was provided for this study. JA consults for Finch Therapeutics, Merck, Artugen, and Servatus. GKG is on the SAB and is a shareholder in ParetoBio, Inc. His interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies. LB, GKG, and JA are co-inventors on patents for defined bacteriotherapeutics against <i>C. difficile</i>.